Completed OBSERVATIONAL NCT00830115

Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders (PANDA)

Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders

Sponsor: Nycomed

Conditions Gastroesophageal Reflux Disease Non-Erosive Reflux Disease Sleep Disorders

Updated 8 times since 2017 Last updated: May 4, 2012 Started: Jan 31, 2009 Primary completion: May 31, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Gastroesophageal Reflux Disease and Non-Erosive Reflux Disease and is currently completed. Nycomed leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed
Sep 2025 — Oct 2025 [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nycomed

Data source: Nycomed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Ahrensburg, Germany , Altenburg, Germany , Ansbach, Germany , Aschaffenburg, Germany , Augsburg, Germany , Bad Bederkesa, Germany , Bad Doberan, Germany , Bad Essen, Germany , Bad Kissigen, Germany and 159 more locations